Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TGFBR1 | P36897 | 17/20 | 0.50 |
| ▸ | BUB1 | O43683 | 2/20 | 0.47 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.41 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.41 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18554152 | 0.90 | TGFBR1 (0.50) | TGFBR1BUB1HDAC3HDAC1HDAC2 | |
| SCHEMBL18554302 | 0.89 | PDGFRA (0.43) | TGFBR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL18554354 | 0.88 | BUB1 (0.51) | TGFBR1BUB1HDAC3HDAC1HDAC2 | |
| SCHEMBL18554246 | 0.88 | TGFBR1 (0.50) | TGFBR1BUB1 | |
| SCHEMBL18554142 | 0.88 | TGFBR1 (0.44) | TGFBR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL18583414 | 0.86 | TGFBR1 (0.52) | TGFBR1BUB1 | |
| SCHEMBL18554474 | 0.86 | TGFBR1 (0.49) | TGFBR1BUB1HDAC3HDAC1HDAC2 | |
| SCHEMBL18554235 | 0.84 | TGFBR1 (0.56) | TGFBR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL18554372 | 0.84 | TGFBR1 (0.56) | TGFBR1HDAC3HDAC1HDAC2HDAC8 | |
| SCHEMBL18583361 | 0.83 | TGFBR1 (0.47) | TGFBR1BUB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL MYERS SQUIBB CO (US) | 2018-09-06 | — | — | US | disclosed |
| EP-3341372-A1 | TGF BETA RECEPTOR ANTAGONISTS | Bristol-Myers Squibb Company (US) | 2018-07-04 | — | — | EP | disclosed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
| WO-2017035118-A1 | TGF BETA RECEPTOR ANTAGONISTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2017-03-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180250303-A1 | TGF BETA RECEPTOR ANTAGONISTS | TGFBR1, TGFBR2, TGFB1 | TGFBR1 1/4885BUB1 338/4885HDAC3 1362/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.